Addus HomeCare (ADUS) reported $373.08 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 25.6%. EPS of $1.77 for the same period compares to $1.38 a year ago.
The reported revenue represents a surprise of +0.94% over the Zacks Consensus Estimate of $369.61 million. With the consensus EPS estimate being $1.71, the EPS surprise was +3.27%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Addus HomeCare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Personal care: $285.98 million versus $282.11 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +29.8% change.
- Revenue- Home Health: $17.1 million compared to the $17.37 million average estimate based on two analysts. The reported number represents a change of -4.1% year over year.
- Revenue- Hospice: $70 million versus $69.14 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +18.7% change.
View all Key Company Metrics for Addus HomeCare here>>>
Shares of Addus HomeCare have returned +4.6% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Addus HomeCare Corporation (ADUS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
